{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:06:19Z","timestamp":1761523579026},"reference-count":27,"publisher":"Informa UK Limited","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Investigation"],"published-print":{"date-parts":[[2007,1]]},"DOI":"10.1080\/07357900701518388","type":"journal-article","created":{"date-parts":[[2007,12,6]],"date-time":"2007-12-06T06:32:25Z","timestamp":1196922745000},"page":"711-714","source":"Crossref","is-referenced-by-count":13,"title":["Adjuvant Therapy with Raltitrexed in Patients with Colorectal Cancer Intolerant of 5-Fluorouracil: British Columbia Cancer Agency Experience"],"prefix":"10.1080","volume":"25","author":[{"given":"Kenneth S.","family":"Wilson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine A.","family":"Fitzgerald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeff B.","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Pharm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharlene","family":"Gill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kong E.","family":"Khoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2009,6,11]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.56.2.106"},{"key":"CIT0002","first-page":"939","volume":"345","author":"Efficacy o f","year":"1995","journal-title":"International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet"},{"key":"CIT0003","first-page":"444","volume":"264","year":"1990","journal-title":"J. Am. Med. Assoc."},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-003-0330-z"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1998.421"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(95)00502-1"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)00320-7"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1998.652"},{"key":"CIT0009","volume-title":"BCCA Protocol Summary for palliative chemotherapy for metastatic colorectal cancer using raltitrexed in patients with previous fluoro-uracil toxicity","author":"British Columbia Cancer Agency GI Tumour Group"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1081\/CNV-120005915"},{"key":"CIT0011","volume-title":"BCCA Protocol Summary for stage III and high risk stage II colon cancer using leucovorin and fluorouracil","author":"British Columbia Cancer Agency GI Tumour Group"},{"key":"CIT0012","volume-title":"BCCA Protocol Summary for rectal carcinoma using fluorouracil + leucovorin + XRT","author":"British Columbia Cancer Agency GI Tumour Group"},{"key":"CIT0013","first-page":"113","volume-title":"American Joint Committee on Cancer: AJCC Cancer Staging Manual. 6th edition","year":"2002"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"CIT0015","first-page":"1","volume":"35","author":"Peto R","year":"1977","journal-title":"Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Part II: Analysis and Examples. Brit. J. Cancer"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1016\/S0093-7754(01)90246-5"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043116"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-200002000-00025"},{"key":"CIT0019","author":"Weinerman B","year":"1996","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.6.1491"},{"key":"CIT0021","author":"Zalcberg J","year":"1996","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-199708002-00004"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602783"},{"key":"CIT0024","first-page":"739","volume":"69","author":"Shah A","year":"1985","journal-title":"Cancer Treatment Reports"},{"issue":"4","key":"CIT0025","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3390\/curroncol12040003","volume":"12","author":"Browman G","year":"2005","journal-title":"Current Oncology"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.6071"},{"key":"CIT0027","volume-title":"BCCA Protocol Summary for Adjuvant Therapy of Colon Cancer using Capecitabine","author":"British Columbia Cancer Agency GI Tumour Group"}],"container-title":["Cancer Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/07357900701518388","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T04:29:38Z","timestamp":1684124978000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/full\/10.1080\/07357900701518388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":27,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2009,6,11]]},"published-print":{"date-parts":[[2007,1]]}},"alternative-id":["10.1080\/07357900701518388"],"URL":"https:\/\/doi.org\/10.1080\/07357900701518388","relation":{},"ISSN":["0735-7907","1532-4192"],"issn-type":[{"value":"0735-7907","type":"print"},{"value":"1532-4192","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,1]]}}}